| | Study | Stem cell | Animal | Cancer cell | Transplantation | Prodrug injection | in vivo tracking | Prodrug system | Injected dose of therapeutic stem cells | Transduction | Therapeutic stem cell |
| | Lee et al., [23] | Human NSC | C57BL/6 mice | TRAMPC2 | Left ventricle injection, 5 weeks after injection of cancer cells | Intraperitoneally, 500 g/kg/day in three rounds of 5 consecutive days with a break of 2 days | MNP | Bacterial CD/5-FC | cells/100 L saline | Retrovirus | HB1.F3.CD |
| | Song et al., [51] | Rat BM-MSC | Nude mice | PC3 | Intravenous, 10 and 20 days after injection of cancer cells | Intramuscularly, 30 mg/kg each time for 5 consecutive days for 2 cycles, | GFP | HSV-tk/GCV | cells/kg | Lentivirus | TK-BMSC |
| |
Cavarretta et al., [32] | Human AT-MSC | Nude mice | Du145, PC3
LNCaP
PC3 (only for in vivo) | Intravenous, same time with cancer cell injection | Intraperitoneally, 500 g/kg/day daily, starting on second day after tumor appearance up to 27 or 32 days | None | yeast CD: UPRT/5-FC | cells/200 L PBS | Retrovirus | CDy-AT-MSC |
| | Ren et al., [52] | Mice BM-MSC | C57BL/6 mice | TRAMPC2 | Intravenous, twice, 10 days after injection of cancer cells | None | GFP | None | cells/200 L saline | Adenoassociated virus | MSC-AAV-IFN- |
| | Yi et al., [46] | Human NSC | None | LNCaP | None | None | None | Bacterial CD/5-FC, Rabbit CE/CPT-11, Bacterial CD/Human IFN- | None | Leukemia virus | HB1.F3.CE, HB1.F3.CD, HB1.F3.CD.IFN- |
| | Lee et al., Immortalized [39] | Human BMSC | Nude mice | Du145, PC3 | Intravenous, 10 days after injection of cancer cells | Intraperitoneally, 30 mg/kg in every round for 5 consecutive days | GFP | HSV-tk/GCV | cells/kg | Lentivirus | SV40-TK-hfBMSC |
|
|
